Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells

Hassan, Firas; El‐Hiti, Gamal A.; Abd-Allateef, Mays; Yousif, Emad

doi:10.15537/smj.2017.4.17061

Cited by 22 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nuclear intensities following treatment with other tamoxifen concentrations (50-6.25 µg/mL) showed no significant difference (25.49%-4.10%) compared with the control (P < 0.0001). Similar results were previously obtained following treatment of MCF7 cells with anastrozole [27] . MCF7: breast cancer cell line; MMP: mitochondrial membrane potential; CV: cell viability; NI: nuclear intensity; CP: cell permeability; CC: cytochrome c; LSD: least significant difference.…”

Section: Nuclear Intensitysupporting

confidence: 89%

See 1 more Smart Citation

Cytotoxic effects of tamoxifen in breast cancer cells

Hassan¹,

Jassam²,

El‐Hiti³

et al. 2018

JUMD

Self Cite

View full text Add to dashboard Cite

Aim: To investigate the cytotoxic effects of tamoxifen on the breast cancer cell line (MCF7). Methods:The cytotoxic effects of tamoxifen on MCF7 cells were investigated using caspase-9 activity and high content screening assays. Apoptosis mechanisms following tamoxifen treatment were also investigated. Results:The most significant cytotoxic effect of tamoxifen in MCF7 cells was a half-maximal inhibitory concentration (IC 50 ) of 4.506 µg/mL. A significant increase in caspase-9 activity was also observed when MCF7 cells were treated with tamoxifen (5 µg/mL). Furthermore, increased cell membrane permeability, cytochrome c level, and nuclear intensity were observed with tamoxifen (100 µg/mL) compared with doxorubicin (20 µg/mL) treatment. However, a noticeable decrease in cell viability and mitochondrial membrane permeability was observed with tamoxifen (100 µg/mL) treatment compared with doxorubicin (20 µg/mL) as a positive control. Conclusion:Tamoxifen showed in vitro cytotoxic effects in MCF7 cells as demonstrated by high-content screening and caspase-9 activity assays. Tamoxifen inhibits estrogen mechanisms, although toxic effect was observed.

show abstract

Section: Nuclear Intensitysupporting

confidence: 89%

“…We have previously investigated the cytotoxicity and anticancer activities of several aryl phosphonates on MCF7 cells [25] . Recently, we also reported the cytotoxic activities of anastrozole in several cancer cell lines [26,27] . In the current study, we report the cytotoxic effects of tamoxifen in MCF7 cancer cells.…”

Section: Introductionmentioning

confidence: 97%

Cytotoxic effects of tamoxifen in breast cancer cells

Hassan¹,

Jassam²,

El‐Hiti³

et al. 2018

JUMD

Self Cite

View full text Add to dashboard Cite

show abstract

“…Anastrozole is an aromatase inhibitor and therefore prevents the conversion of androgens to oestrogens, and is used as an anti-breast cancer treatment. 2 Mrs X underwent a left nipple-sparing mastectomy and immediate reconstruction using a free abdominal based flap. The mastectomy involved an elliptical incision to excise the previous lumpectomy scars and the underlying breast tissue.…”

Section: Case Presentationmentioning

confidence: 99%

The Choice of Abdominal Flap Used in Breast Reconstruction Surgery

McVeigh¹,

Kalu²

2020

JNDS

View full text Add to dashboard Cite

The incidence of breast cancer has been progressively increasing to the current level where 1 in 8 women now develop the disease. The National Breast Screening Programme has enabled us to diagnose many breast cancers at a much earlier stage. Coupled with an improved understanding of the oncoplastic approach to breast cancer surgery, genomics, hormone and targeted therapies as well as chemotherapy we now anticipate better outcomes. Despite the many advances in breast cancer there remains a significant cohort of women who are diagnosed with advanced forms of the disease that necessitates mastectomy i.e. the removal of all breast tissue. For many, reconstruction maybe immediately possible at the same time as mastectomy using either non-autologous (man-made) options such as breast implants and tissue expanders or autologous options using the latissimus-dorsi, abdominal or non-abdominal based flaps sited on thigh, buttock or lower flank tissue. Abdominal based reconstructions have evolved from crude operative procedures in which large parts of the lower anterior abdominal wall were harvested while remaining attached to the feeding vascular supply. This ‘flap’ of tissue is then rotated upon the pedicle of vessels into the new location in the breast. Pedicled Transverse Rectus Abdominus Myocutaneous (TRAM) flaps were often complicated by under-perfusion of the transferred flap resulting in fat necrosis. There were also issues with abdominal wall bulges and hernias as a result of the loss of the rectus abdominus muscle. With improvements in microsurgery the advent of free flap surgery was ushered in. Skin and fat were transplanted from the lower anterior abdominal wall using one of the rectus abdominus muscles and the perfusing artery and draining vein (donor-site). This free TRAM flap could be transplanted in the recipient-site after re-joining (re-anastomosing) the artery and vein using microsurgery. Aided by better anatomical knowledge, surgeons have been able to reduce the amount of rectus muscle sacrificed resulting in the muscle sparing-TRAM (MS-TRAM) and more latterly the deep inferior epigastric perforator (DIEP) flap which has no muscle included. The advantages of this muscle sparing approach are speedier recovery and reduced morbidity while maintaining operative cosmetic outcomes.

show abstract

“…AIs have been shown to exhibit cytotoxic effects in various cancer cell lines (30,31) and NCI-60 ( Fig. 1) (28).…”

Section: New Ai Predictorsmentioning

confidence: 99%

Evaluation of drug-specific multigene markers to predict aromatase inhibitor efficacy in advanced breast cancer: a cohort study from Danish Breast Cancer Cooperative Group

Buhl¹,

Christensen

Buhl³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Even with positive oestrogen receptor (ER+) status some advanced breast cancer (ABC) patients fail to benefit from endocrine therapy (ET). A method that previously predicted other drugs in various cancers was evaluated. Here multigene markers based on aromatase inhibitor (AI) effect in vitro were used for prediction of AI benefit in ER+ ABC patients. Simultaneously effects of long-term ET on predictive efficacy was evaluated. Methods The Drug Response Predictors (DRPs) are based on correlations between baseline gene expression and growth inhibition patterns of exemestane, anastrozole and letrozole, respectively, in the National Cancer Institute 60 cell lines. The genes were controlled for expression in 3,500 tumours. In a Danish Breast Cancer Cooperative Group cohort of 695 ABC patients with complete gene expression and time-to-progression (TTP) data, 414 received an AI as monotherapy. Hereof, 57 received anastrozole, 166 received exemestane, and 327 received letrozole. mRNA was isolated from archival formalin-fixed paraffin embedded tumour tissue and run on microarray and 60% of the tumours were from time of primary diagnosis. Medical records of the patients were assessed for TTP for all treatments given for ABC. Results The DRPs were tested in subsets 1) with no adjuvant ET and 2) with adjuvant ET. In 1) the anastrozole DRP predicted benefit of anastrozole (hazard ratio (HR) was 0.21 upper 95%-confidence interval limit (CI) 0.76, p=0.023) but not in 2). Dichotomised by a DRP of 50, the anastrozole DRP did predict benefit (HR=0.16, upper 95%-CI 0.75, p=0.026). Only in 1) the exemestane DRP predicted benefit of exemestane (HR=0.57, upper 95%-CI 1.00, p=0.0497). The letrozole DRP had no predictive value. Additionally, we tested each DRPs ability to predict other AIs. Only the anastrozole DRP predicted benefit of overall AI treatment, in 1)with an HR of 0.76 (upper 95%-CI 0.99, p=0.044) and in 2) with an HR of 0.71 (upper 95%-CI 0.92, p=0.015). The anastrozole DRP did though not predict benefit of letrozole. All tests are one-sided, alpha=5%. Conclusions Among the DRPs for AIs, the anastrozole DRP was strongest with clinically relevant prediction of TTP in AI treated ER+ ABC patients. Trial registration: ClinicalTrials.gov NCT01861496. BackgroundApproximately 70% of women with advanced breast cancer (ABC) have oestrogen-receptor positive

show abstract

Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells

Cited by 22 publications

References 28 publications

Cytotoxic effects of tamoxifen in breast cancer cells

Cytotoxic effects of tamoxifen in breast cancer cells

The Choice of Abdominal Flap Used in Breast Reconstruction Surgery

Evaluation of drug-specific multigene markers to predict aromatase inhibitor efficacy in advanced breast cancer: a cohort study from Danish Breast Cancer Cooperative Group

Contact Info

Product

Resources

About